Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13229	GDC-0575
BP13229	GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor(IC50 of 1.2 nM).
BP13230	GDC0575 monohydrochloride
BP13230	GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.
BP13231	Gentamicin sulfate
BP13231	Gentamycin Sulfate is a wide-spectrum, aminoglycoside antibiotic used to inhibit protein synthesis in sensitive organisms.
BP13232	Gentisin
BP13232	Gentisin is a novel inhibitor of vascular smooth muscle cells (VSMC) proliferation with an IC50 value of 7.84 μM. Gentisin has mutagenic activity.
BP13233	Ginsenoside C-K
BP13233	Ginsenoside C-K is a bacterial metabolite of G-Rb1 exhibiting anti-inflammatory effects by reducing iNOS and COX-2.
BP13234	GNE-6640
BP13234	GNE-6640 is a non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC50 values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP43 and Ub-MDM2, respectively.
BP13235	GNE-6776
BP13235	GNE-6776 is a selective USP7 inhibitor.
BP13236	GNF2133
BP13236	GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
BP13237	GNF4877
BP13237	GNF4877 is a potent DYRK1A and GSK3β inhibitor (IC50s: 6 nM and 16 nM). It leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation cells.
BP13238	Gracillin
BP13238	Gracillin can induce cell cycle arrest, oxidative stress, and apoptosis in HL60 cells, and has the potential to be developed as an antitumor agent. Gracillin can be selected as lead compounds for the development of new drugs against I. multifiliis.
BP13239	GRL0617
BP13239	GRL0617 is a selective and competitive SARS-CoVPLpro and deubiquitinase noncovalent inhibitor(IC50 : 0.6 μM, Ki : 0.49 μM).
BP13240	GS-441524
BP13240	GS-441524 treatment of cats with naturally occurring feline infectious peritonitis.
BP13241	GSK180736A
BP13241	GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effective against ROCK1 (IC50: 100 nM).
BP13242	GSK-25
BP13242	GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC50 of 398 nM, p70S6K IC50 of 1000nM), and a dramatically improved P450 profile (>2.2 uM at all isozymes tested).
BP13243	GSK2643943A
BP13243	GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor (IC50: 160 nM for USP20/Ub-Rho).
BP13244	GSK269962A
BP13244	GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
BP13245	GSK2850163
BP13245	GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit RNase activity and IRE1α kinase activity (IC50s: 200 and 20 nM).
BP13246	GSK429286A
BP13246	GSK429286A is a specific inhibitor of ROCK1/2 (IC50: 14/63 nM).
BP13247	GSK461364
BP13247	GSK461364(Ki=2.2 nM) inhibits purified Plk1.The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
BP13248	GSK-626616
BP13248	GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.